Waldenström's Macroglobulinemia

Table of Contents

  1. What is Waldenström's Macroglobulinemia?
  2. Genetics: MYD88 L265P and CXCR4 Mutations
  3. Pathophysiology: IgM Monoclonal Protein
  4. Hyperviscosity Syndrome
  5. Clinical Symptoms and Presentations
  6. Diagnosis: Tests and Criteria
  7. IgM MGUS vs. Waldenström's
  8. Treatment Approaches
  9. Prognosis and Disease Course
  10. Special Considerations
  11. Key Research Papers
  12. Connections
  13. Featured Videos

What is Waldenström's Macroglobulinemia?

Waldenström's macroglobulinemia (WM) is a rare, slow-growing blood cancer — technically a lymphoplasmacytic lymphoma (LPL) — in which abnormal B cells invade the bone marrow and produce large quantities of a protein called IgM (immunoglobulin M). It is named after Jan Waldenström, the Swedish physician who first described the disease in 1944. WM falls in the spectrum between non-Hodgkin lymphoma and plasma cell disorders; it shares features with both CLL and multiple myeloma but is distinct from both. Incidence is approximately 3 per million people per year. Median age at diagnosis is around 70 years, and it is more common in men and in people of European descent.

The disease is typically indolent — many patients live years without needing treatment — but it is currently considered incurable with standard therapy. Despite this, modern treatments have significantly extended survival and quality of life. The discovery of the near-universal MYD88 L265P mutation in 2012 transformed understanding of WM biology and opened the door to targeted therapies, including BTK inhibitors, that have changed the treatment landscape considerably.

Back to Table of Contents

Genetics: MYD88 L265P and CXCR4 Mutations

The genetic landscape of WM is distinctive and clinically actionable. The MYD88 L265P somatic mutation is found in over 90% of WM patients — one of the highest mutation frequencies of any lymphoma. MYD88 is an adaptor protein in the Toll-like receptor (TLR) signaling pathway. The L265P mutation locks MYD88 in an active state, constitutively activating NF-κB and JAK-STAT signaling, driving uncontrolled B cell survival and proliferation. This mutation also activates BTK (Bruton's tyrosine kinase), which explains why BTK inhibitors are so effective in WM.

CXCR4 mutations (somatic WHIM-type mutations) occur in 30–40% of WM patients, often alongside MYD88 L265P. CXCR4 encodes a chemokine receptor involved in cell homing and retention in the bone marrow. CXCR4 mutations affect chemokine signaling and are associated with higher bone marrow tumor burden, higher IgM levels, and reduced responsiveness to BTK inhibitors like ibrutinib. Testing for both mutations has become standard diagnostic practice and guides treatment selection. Patients who are MYD88 wild-type (the small minority without the L265P mutation) have a different biology, a higher risk of transformation, and respond differently to ibrutinib. Patients who are MYD88 L265P mutated but CXCR4 wild-type tend to have the best responses to BTK inhibitors.

Back to Table of Contents

Pathophysiology: IgM Monoclonal Protein

The malignant cells in WM are lymphoplasmacytic cells — B cells partway through their maturation into antibody-secreting plasma cells. They accumulate in the bone marrow, lymph nodes, spleen, and liver. These abnormal cells produce large amounts of a monoclonal IgM protein (M-protein) — a single identical antibody clone with no useful immune function. Normal immune antibody diversity is suppressed as healthy B cell development is crowded out.

IgM is the largest immunoglobulin; its pentameric structure (five antibody units joined by a J-chain) means it is predominantly confined to the bloodstream, unlike IgG which distributes to tissues. The accumulation of high-molecular-weight IgM in the blood is the principal driver of the hallmark complication of WM: hyperviscosity syndrome. Beyond its bulk effects, the IgM protein can have specific pathogenic properties — it may act as a cryoglobulin (precipitating in cold temperatures), bind to nerve myelin causing IgM anti-MAG neuropathy, behave as a cold agglutinin (binding and destroying red blood cells in cold environments), or deposit in tissues as amyloid (AL amyloidosis, which is rare in WM but occurs).

Bone marrow infiltration by lymphoplasmacytic cells impairs normal hematopoiesis, reducing production of red blood cells (causing anemia), white blood cells (increasing infection risk), and platelets (increasing bleeding risk). The expanded plasma volume from high IgM levels further dilutes the red cell mass, compounding anemia.

Back to Table of Contents

Hyperviscosity Syndrome

Hyperviscosity syndrome is the most dramatic acute complication of WM and is considered a medical emergency. Normal serum viscosity is 1.4–1.8 centipoise (cp); symptoms typically begin when viscosity exceeds 4 cp and become severe above 6 cp. Because IgM is pentameric, even modest amounts of serum IgM raise viscosity far more than the same mass of IgG or IgA. Approximately 15–30% of WM patients will experience clinically significant hyperviscosity at some point in their disease course.

Symptoms reflect impaired blood flow through small vessels throughout the body. Visual disturbances are often the first warning sign — blurred vision, double vision, and on fundoscopic exam the classic "sausage-link" appearance of dilated, tortuous retinal veins with possible retinal hemorrhages. Neurological symptoms include headache, dizziness, vertigo, hearing loss, and confusion; in severe cases, stroke can occur. Oronasal bleeding from mucosal vessel fragility is common, and patients may notice spontaneous gum bleeding or nosebleeds. Rarely, high-output cardiac stress from the expanded plasma volume can contribute to congestive heart failure symptoms.

Treatment of hyperviscosity emergency is urgent plasmapheresis (plasma exchange), which rapidly physically removes the IgM protein from the bloodstream and can dramatically relieve symptoms within hours. A critical clinical pitfall: rituximab (anti-CD20 antibody) can paradoxically and transiently increase serum IgM levels in the first weeks of treatment — the so-called "IgM flare" — which can precipitate or worsen hyperviscosity. For this reason, plasmapheresis must be performed before rituximab is given in any patient with symptomatic hyperviscosity. Plasmapheresis is a temporizing measure; definitive reduction in IgM requires systemic WM treatment.

Back to Table of Contents

Clinical Symptoms and Presentations

Beyond hyperviscosity, WM produces a broad range of symptoms reflecting bone marrow infiltration, organomegaly, and the pathogenic effects of circulating IgM. Constitutional (B) symptoms — profound fatigue, drenching night sweats, unintentional weight loss, and recurrent low-grade fever — are common and often represent the presenting complaint. These symptoms reflect the body's chronic inflammatory response to the lymphoma. Physical examination may reveal lymphadenopathy (enlarged lymph nodes in the neck, armpits, or groin), splenomegaly (enlarged spleen, sometimes causing left-sided abdominal fullness), and hepatomegaly from lymphoplasmacytic infiltration.

Anemia, typically normocytic (normal-sized red cells), results from two overlapping mechanisms: marrow crowding by tumor cells suppressing red cell production, and hemodilution from the expanded plasma volume caused by high IgM. This explains why WM patients can feel severely fatigued at hemoglobin levels that might cause only mild symptoms in other anemias.

Peripheral neuropathy affects roughly 20–25% of WM patients, often presenting as a disabling, symmetric, slowly progressive sensory demyelinating neuropathy predominantly affecting the feet and hands. The most characteristic subtype is IgM anti-MAG (myelin-associated glycoprotein) neuropathy: the IgM monoclonal protein in these patients has specific antibody reactivity against MAG, a component of peripheral nerve myelin. Over time, patients experience worsening numbness, tingling, and unsteadiness (ataxic gait) that can significantly impair function. This neuropathy can precede the WM diagnosis by years.

Cold agglutinin disease develops when the IgM antibody acts as a cold agglutinin — binding RBC surface antigens (typically I or i antigens) at lower temperatures in peripheral tissues, triggering complement-mediated red cell destruction (hemolysis). Clinically this causes hemolytic anemia and Raynaud-like acrocyanosis — painful bluish-white discoloration of fingers, toes, nose, and ears triggered by cold exposure. Cryoglobulinemia occurs when the IgM precipitates at low temperatures in vessel walls, causing type I cryoglobulinemia with vasculitis manifestations including palpable purpura, arthralgia, and renal involvement.

Back to Table of Contents

Diagnosis: Tests and Criteria

WM is diagnosed based on a combination of serum protein studies, bone marrow biopsy findings, and molecular testing. There is no single definitive test; the diagnosis requires clinical-pathological integration. Serum protein electrophoresis (SPEP) and immunofixation electrophoresis demonstrate an IgM monoclonal protein (M-spike) in the beta-gamma region. Quantitative serum IgM level measurement correlates with disease burden and hyperviscosity risk — though symptoms and IgM level do not always correlate predictably between patients.

Complete blood count reveals anemia in most symptomatic patients; leukopenia and thrombocytopenia reflect marrow compromise with more advanced disease. Serum beta-2 microglobulin is an important prognostic biomarker reflecting tumor burden and renal function. LDH elevation indicates high tumor turnover. Serum viscosity measurement should be obtained urgently in any patient with symptoms suggesting hyperviscosity.

Bone marrow biopsy is essential and diagnostic — it shows lymphoplasmacytic infiltration with characteristic immunophenotyping by flow cytometry: CD19+, CD20+, CD22+, surface IgM positive, CD138 variably positive, typically CD5 negative, CD10 negative, and CD23 negative. This immunophenotypic pattern helps distinguish WM from CLL (CD5+, CD23+), follicular lymphoma (CD10+), and multiple myeloma (CD138 strongly positive, CD19/20 negative). MYD88 L265P and CXCR4 mutation PCR testing on marrow material is now standard practice. CT scan of the chest, abdomen, and pelvis assesses the extent of lymphadenopathy and organomegaly and screens for transformation to aggressive lymphoma.

Back to Table of Contents

IgM MGUS vs. Waldenström's

IgM MGUS (monoclonal gammopathy of undetermined significance) represents the benign precursor state to WM and must be carefully distinguished from symptomatic WM. The distinction is clinically critical: IgM MGUS requires only surveillance monitoring, while WM may require treatment. Both conditions involve an IgM M-protein detectable in the serum, and the two exist on a biological continuum.

The WHO defines IgM MGUS as an IgM M-protein of any level with less than 10% lymphoplasmacytic infiltration of the bone marrow AND no end-organ damage attributable to the IgM or the lymphoplasmacytic disorder. "End-organ damage" in this context means no clinically significant anemia, hyperviscosity, peripheral neuropathy, organomegaly, or other WM-related complications. WM diagnosis requires either 10% or greater bone marrow infiltration OR the presence of end-organ damage regardless of the bone marrow percentage — even a patient with only 5% bone marrow involvement who has symptomatic hyperviscosity meets criteria for WM requiring treatment.

Annual risk of progression from IgM MGUS to WM or a related lymphoid disorder is approximately 1.5–2% per year. MYD88 L265P is present in 50–80% of IgM MGUS cases, confirming the genetic continuum between MGUS and WM. The presence of this mutation in MGUS does not by itself require treatment — it is a marker of the WM genetic lineage, not an indication for therapy. Regular monitoring with annual serum protein electrophoresis, complete blood count, and careful symptom review is the standard approach for IgM MGUS. More frequent monitoring may be appropriate for patients with higher IgM levels or rising M-spikes.

Back to Table of Contents

Treatment Approaches

Many patients with WM are asymptomatic at diagnosis and require no immediate treatment. A watch-and-wait approach is appropriate and proven not to worsen outcomes — initiating therapy earlier in asymptomatic patients does not prolong survival and exposes patients to treatment toxicity unnecessarily. Treatment is initiated for symptomatic disease: hyperviscosity symptoms, significant anemia (hemoglobin below 10 g/dL), symptomatic lymphadenopathy or organomegaly, progressive cytopenias, constitutional symptoms impairing quality of life, or serious IgM-mediated complications such as disabling neuropathy, cold agglutinin hemolysis, or cryoglobulinemia vasculitis.

First-line regimens include bendamustine plus rituximab (BR) — a highly effective, well-tolerated combination with deep and durable responses that has become the standard chemoimmunotherapy choice for most patients requiring treatment. DRC (dexamethasone, rituximab, cyclophosphamide) is an older but effective oral regimen with lower toxicity, well suited for frail patients or those who cannot tolerate bendamustine. Both regimens include rituximab, and both carry the risk of the IgM flare phenomenon noted above.

BTK inhibitors represent the most significant advance in WM treatment in recent years. Ibrutinib was the first BTK inhibitor approved by the FDA for WM (2015) and produces excellent, durable responses, particularly in patients with MYD88 L265P. Zanubrutinib (second-generation BTK inhibitor, FDA approved for WM in 2021) has superior selectivity — fewer off-target kinase effects — resulting in lower rates of atrial fibrillation and bleeding than ibrutinib, with comparable or better efficacy in head-to-head comparison. CXCR4-mutated patients respond less robustly to ibrutinib; zanubrutinib partially overcomes this limitation. BTK inhibitors are taken as continuous oral therapy until disease progression or intolerance, making them a long-term daily commitment. Bortezomib-based regimens (such as VDR: bortezomib, dexamethasone, rituximab) are alternatives with activity independent of MYD88 mutation status. Autologous stem cell transplantation can be considered for younger, fit patients with relapsed or refractory disease. Plasmapheresis remains the emergency treatment for hyperviscosity and is also used as a bridging measure before initiating rituximab in patients with high IgM levels.

Back to Table of Contents

Prognosis and Disease Course

WM is generally an indolent disease with a heterogeneous course. Median survival in published series is 5–10 years, though many patients — particularly those with low-risk disease — live considerably longer. The BTK inhibitor era has substantially extended survival expectations beyond historical figures. Many patients cycle through multiple lines of therapy over years while maintaining good quality of life between treatments.

The International Prognostic Scoring System for WM (IPSSWM), developed from pooled international data, stratifies patients using five adverse prognostic factors: age greater than 65 years; hemoglobin 11.5 g/dL or less; platelet count 100 × 10⁹/L or less; serum beta-2 microglobulin above 3 mg/L; and serum IgM above 70 g/L. Patients with zero or one adverse factor (low risk) have a median survival exceeding 10 years; those with two factors (intermediate risk) have a median around 7 years; and those with three or more adverse factors (high risk) have a median survival in the range of 3–4 years with older therapies. Newer treatments have shifted these survival curves upward.

Transformation to diffuse large B-cell lymphoma (DLBCL) — a Richter-like transformation analogous to what occurs in CLL — happens in fewer than 5% of WM patients but carries a poor prognosis with median survival under one year after transformation. Clues to transformation include rapidly rising LDH, new constitutional symptoms, or sudden progression after a period of stability. Disease recurrence after initial therapy is expected — WM is not cured by standard therapy — and most patients require multiple lines of treatment over their disease course. Assessing response uses a combination of serum IgM levels, bone marrow response, and clinical improvement.

Back to Table of Contents

Special Considerations

Several important practical considerations apply specifically to people living with WM. Management of IgM-mediated end-organ complications requires individualized attention alongside anti-WM systemic therapy. For peripheral neuropathy — particularly IgM anti-MAG neuropathy — neurological co-management is valuable; IVIG may provide modest benefit for some patients, and rituximab-based systemic therapy can stabilize or improve neuropathy, though responses are slow. Patients with IgM anti-MAG neuropathy should be counseled that neurological improvement after treatment often lags behind hematologic response by many months.

For cold agglutinin disease, cold avoidance is a practical first-line measure — wearing gloves, avoiding cold beverages, keeping the home warm. Rituximab-based therapy can reduce cold agglutinin IgM titers and improve hemolysis. Blood transfusions, when needed, must be given through an in-line blood warmer to prevent cold agglutinin-triggered hemolysis in the transfusion tubing. For cryoglobulinemia, rituximab-based WM therapy is generally effective; trigger avoidance (cold, excessive exercise) helps symptomatically.

Infection susceptibility is increased in WM due to immunosuppression from both the underlying disease (suppression of normal immunoglobulin production) and its treatments. Vaccination with pneumococcal (both PCV and PPSV23) and annual influenza vaccines is recommended for all WM patients. Live vaccines should be avoided during active treatment with rituximab or BTK inhibitors. During ibrutinib or zanubrutinib therapy, aspergillosis and pneumocystis pneumonia prophylaxis may be considered in higher-risk patients.

Regular monitoring during watch-and-wait includes clinic visits every 3–6 months with serum protein electrophoresis, complete blood count, and clinical symptom review. Any sudden new symptoms — visual changes, new neurological symptoms, or rapidly worsening fatigue — should prompt urgent evaluation rather than waiting for the next scheduled appointment. Patients and families benefit from connecting with the International Waldenstrom's Macroglobulinemia Foundation (IWMF) for peer support and updated educational resources.

Back to Table of Contents

Key Research Papers

Molecular Genetics

  1. Treon SP, et al. (2012). MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. PMID: 23339787
  2. Treon SP, et al. (2015). CXCR4 mutations and their role in Waldenström's macroglobulinemia. Leuk Lymphoma. PMID: 27206470

Treatment — BTK Inhibitors

  1. Treon SP, et al. (2014). Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. PMID: 25156862
  2. Dimopoulos MA, et al. (2020). Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances. PMID: 32187463

Treatment — Chemoimmunotherapy

  1. Treon SP, et al. (2001). CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother. PMID: 11535503
  2. Kastritis E, et al. (2015). Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. PMID: 25940712
  3. Rummel MJ, et al. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. PMID: 24150220

Guidelines and Consensus

  1. Dimopoulos MA, et al. (2016). Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 Consensus. Blood. PMID: 27160944
  2. Buske C, et al. (2018). Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. PMID: 30773953

Prognosis and Neuropathy

  1. Morel P, et al. (2009). International prognostic scoring system for Waldenström macroglobulinemia. Blood. PMID: 17393374
  2. Noy A, et al. (2013). IgM anti-MAG neuropathy in Waldenström macroglobulinemia. J Clin Oncol. PMID: 22498019
  3. Gertz MA (2017). Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. PMID: 29222186

PubMed Topic Searches

  1. Waldenström macroglobulinemia treatment
  2. MYD88 L265P lymphoplasmacytic lymphoma
  3. Ibrutinib zanubrutinib Waldenstrom
  4. IgM hyperviscosity syndrome plasmapheresis
  5. IgM anti-MAG neuropathy

Back to Table of Contents

Connections

Back to Table of Contents